MDS 2026 — Precision Medicine in Parkinson's Disease

MDS 2026 — Precision Medicine in Parkinson's Disease

Congress: Movement Disorder Society (MDS) International Congress 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Dates: October 4-8, 2026

This page synthesizes precision medicine advances in Parkinson's disease (PD) presented at MDS 2026, focusing on genetic stratification, polygenic risk scores, biomarker-guided therapies, and personalized treatment approaches that are moving the field toward individualized patient care.

Executive Summary

MDS 2026 featured significant progress in precision medicine for Parkinson's disease, with key themes including:

• Genetic stratification becoming standard for clinical trial enrichment
• Polygenic risk scores (PRS) moving toward clinical implementation
• Biomarker-guided therapy selection based on molecular subtypes
• Personalized treatment algorithms integrating genetic, clinical, and biomarker data
• Combination therapies targeting multiple disease mechanisms in genetically defined subgroups

1. Genetic Stratification in Clinical Practice

1.1 Current Standard of Care

Genetic testing is increasingly considered standard for patients with Parkinson's disease, particularly for:

MDS 2026 — Precision Medicine in Parkinson's Disease

Congress: Movement Disorder Society (MDS) International Congress 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Dates: October 4-8, 2026

This page synthesizes precision medicine advances in Parkinson's disease (PD) presented at MDS 2026, focusing on genetic stratification, polygenic risk scores, biomarker-guided therapies, and personalized treatment approaches that are moving the field toward individualized patient care.

Executive Summary

MDS 2026 featured significant progress in precision medicine for Parkinson's disease, with key themes including:

• Genetic stratification becoming standard for clinical trial enrichment
• Polygenic risk scores (PRS) moving toward clinical implementation
• Biomarker-guided therapy selection based on molecular subtypes
• Personalized treatment algorithms integrating genetic, clinical, and biomarker data
• Combination therapies targeting multiple disease mechanisms in genetically defined subgroups

1. Genetic Stratification in Clinical Practice

1.1 Current Standard of Care

Genetic testing is increasingly considered standard for patients with Parkinson's disease, particularly for:

| Gene | Testing Recommendation | Therapeutic Implication |
|------|----------------------|------------------------|
| GBA1 | Recommended for all PD patients | Enzyme enhancement, substrate reduction |
| LRRK2 | Recommended for all PD patients | Kinase inhibitor eligibility |
| SNCA | Recommended for early-onset/familial | Immunotherapy considerations |
| VPS35 | Consider in typical PD | Research status |
| PARK2 (PRKN) | Early-onset patients | Gene therapy potential |

1.2 Clinical Utility

MDS 2026 highlighted the clinical utility of genetic stratification:

1.3 Implementation Challenges

| Challenge | Current Solution | Future Direction |
|-----------|-----------------|------------------|
| Testing access | Multi-gene panels | Population-based screening |
| Variant interpretation | ACMG guidelines | Machine learning classifiers |
| Result disclosure | Genetic counseling | Standardized protocols |
| Data sharing | Institutional silos | International registries |

2. Polygenic Risk Scores for PD

2.1 Development Status

Polygenic risk scores aggregate the effects of thousands of genetic variants to quantify individual genetic predisposition to PD[@nalls2019][@blauwendraat2020].

2.2 Performance Metrics

Current PD PRS performance:

• AUC-ROC: ~0.65-0.70 for population stratification
• Risk stratification: Top decile has ~3-4x increased risk vs. bottom decile
• Variance explained: ~5-8% of disease variance

2.3 Clinical Applications at MDS 2026

| Application | Current Status | Notes |
|-------------|---------------|-------|
| Primary prevention | Research | Identifying high-risk individuals for prevention trials |
| Clinical trial enrichment | Emerging | Enriching trials for rapid progressors |
| Prognostic stratification | Research | Predicting disease progression rate |
| Therapeutic targeting | Research | Matching patients to targeted therapies |

2.4 Integration with Monogenic Risk

Combining monogenic variants with polygenic risk scores provides more precise risk estimation:

| Genetic Category | Risk Multiplier | PRS Contribution |
|-----------------|-----------------|------------------|
| LRRK2 G2019S | 5-10x | Additive with PRS |
| GBA severe | 10-20x | Additive with PRS |
| SNCA duplication | 10-15x | Additive with PRS |
| High PRS (top decile) | 3-4x | Independent effect |
| Combined (high PRS + mutation) | Up to 50x | Synergistic |

3. Biomarker-Guided Therapy Selection

3.1 Molecular Subtypes

MDS 2026 highlighted the identification of distinct molecular subtypes in PD:

| Subtype | Biomarker Signature | Therapeutic Approach |
|---------|-------------------|----------------------|
| Synucleinopathy | pSer129 α-syn, RT-QuIC+ | Anti-α-syn therapies |
| Tauopathic | Elevated 4R tau, PET+ | Anti-tau therapies |
| Inflammatory | Elevated CSF IL-6, TREM2 | Immunomodulation |
| Mitochondrial | Complex I deficiency | Mitochondrial protectants |
| Lysosomal | Low GCase, elevated Lyso-Gb1 | Enzyme enhancement |

3.2 Biomarker Integration Framework

The AT(N) framework (adapted from Alzheimer's disease) was discussed for PD:

| Biomarker | Measure | Clinical Use |
|-----------|---------|--------------|
| A (Alpha-synuclein) | CSF pSer129, RT-QuIC | Diagnosis, stratification |
| T (Tau) | PET, CSF total tau | Differential diagnosis |
| N (Neurodegeneration) | NfL, DAT imaging | Progression tracking |

3.3 Precision Medicine Algorithm

4. Personalized Treatment Approaches

4.1 Genotype-Guided Therapeutics

| Genetic Subtype | Primary Target | Drug Candidates | Status |
|----------------|---------------|-----------------|--------|
| GBA-PD | GCase enhancement | Ambroxol, GT-02287 | Phase 2/3 |
| GBA-PD | Substrate reduction | Venglustat | Phase 2 |
| GBA-PD | Gene therapy | PR001, PBFT02 | Phase 1/2 |
| LRRK2-PD | Kinase inhibition | DNL151, BIIB122 | Phase 2/3 |
| LRRK2-PD | ASO therapy | Multiple | Preclinical |
| SNCA-PD | Anti-α-syn immunotherapy | Cinamerne, UB-312 | Phase 1/2 |
| SNCA-PD | ASO therapy | SNCA-targeting | Phase 1 |
| LRRK2 + GBA | Combination | LRRK2i + Chaperone | Preclinical |

4.2 Disease Modification vs. Symptomatic Treatment

Precision medicine distinctions:

| Treatment Goal | Traditional Approach | Precision Approach |
|----------------|---------------------|-------------------|
| Disease modification | All PD patients | Genetically selected subgroups |
| Symptomatic control | Levodopa-responsive | Subtype-specific combinations |
| Prevention | None | High-PRS + environmental modification |

4.3 Combination Therapy Strategies

MDS 2026 featured emerging combination approaches:

5. Clinical Implementation

5.1 Precision Medicine Workflow

| Step | Action | Output |
|------|--------|--------|
| 1 | Clinical diagnosis | PD phenotype |
| 2 | Genetic testing | Mutation status |
| 3 | Biomarker assessment | Molecular subtype |
| 4 | PRS calculation | Risk percentile |
| 5 | Integration | Personalized protocol |

5.2 Barriers to Implementation

| Barrier | Current Status | Solutions Discussed |
|---------|---------------|---------------------|
| Cost | High | Insurance coverage expansion |
| Access | Limited | Centralized testing facilities |
| Interpretation | Complex | AI-assisted variant classification |
| Turnaround | Weeks | Rapid sequencing technologies |
| Counselling | Limited workforce | Training programs |

5.3 Health Equity Considerations

MDS 2026 addressed important equity considerations:

• Ancestry bias: PRS trained primarily on European ancestry
• Access disparities: Genetic testing availability
• Cultural factors: Variant disclosure practices

• Multi-ethnic PRS development
• Global variant databases
• Population-specific therapeutic responses

6. Emerging Technologies

6.1 Digital Phenotyping

Integration with precision medicine:

• Smartphone-based assessments: Continuous motor monitoring
• Wearable sensors: Activity and gait analysis
• Voice analysis: Speech pattern changes

6.2 Multi-Omics Integration

| Data Type | Clinical Application |
|-----------|---------------------|
| Genomics | PRS, variant identification |
| Proteomics | Biomarker panels |
| Metabolomics | Metabolic subtypes |
| Microbiome | Environmental interaction |
| Epigenomics | Age acceleration |

6.3 Artificial Intelligence

AI applications in precision medicine:

• Variant interpretation: Deep learning classifiers
• Biomarker integration: Multi-modal prediction models
• Treatment response: Predictive algorithms
• Drug discovery: Target identification

7. Future Directions

7.1 Near-Term Goals (2026-2028)

7.2 Long-Term Vision (2028-2035)

8. Related Pages

• [GBA Gene](/genes/gba)
• [LRRK2 Gene](/genes/lrrk2)
• [SNCA Gene](/genes/snca)
• [Polygenic Risk Scores in Neurodegeneration](/mechanisms/polygenic-risk-scores-neurodegeneration)
• [MDS 2026 — GBA and LRRK2 Genetic Susceptibility](/events/mds-2026-gba-lrrk2-genetic-susceptibility)
• [MDS 2026 — Genetics and Biomarkers](/biomarkers/mds-2026-genetics-biomarkers-movement-disorders)
• [Precision Medicine in Neurodegeneration](/mechanisms/precision-medicine-neurodegeneration)
• [Parkinson's Disease](/diseases/parkinsons-disease)

9. References